keyword
MENU ▼
Read by QxMD icon Read
search

rheumatologic emergencies

keyword
https://www.readbyqxmd.com/read/28000011/public-health-awareness-of-autoimmune-diseases-after-the-death-of-a-celebrity
#1
Nicola Luigi Bragazzi, Abdulla Watad, Francesco Brigo, Mohammad Adawi, Howard Amital, Yehuda Shoenfeld
Autoimmune disorders impose a high burden, in terms of morbidity and mortality worldwide. Vasculitis is an autoimmune disorder that causes inflammation and destruction of blood vessels. Harold Allen Ramis, a famous American actor, director, writer, and comedian, died on the February 24, 2014, of complications of an autoimmune inflammatory vasculitis. To investigate the relation between interests and awareness of an autoimmune disease after a relevant event such as the death of a celebrity, we systematically mined Google Trends, Wikitrends, Google News, YouTube, and Twitter, in any language, from their inception until October 31, 2016...
December 20, 2016: Clinical Rheumatology
https://www.readbyqxmd.com/read/27993829/filgotinib-glpg0634-gs-6034-an-oral-jak1-selective-inhibitor-is-effective-in-combination-with-methotrexate-mtx-in-patients-with-active-rheumatoid-arthritis-and-insufficient-response-to-mtx-results-from-a-randomised-dose-finding-study-darwin-1
#2
R Westhovens, P C Taylor, R Alten, D Pavlova, F Enríquez-Sosa, M Mazur, M Greenwald, A Van der Aa, F Vanhoutte, C Tasset, P Harrison
OBJECTIVES: To evaluate the efficacy and safety of different doses and regimens of filgotinib, an oral Janus kinase 1 inhibitor, as add-on treatment to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) and inadequate response to MTX. METHODS: In this 24-week phase IIb study, patients with moderate-to-severe active RA receiving a stable dose of MTX were randomised (1:1:1:1:1:1:1) to receive placebo or 50, 100 or 200 mg filgotinib, administered once daily or twice daily...
December 19, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27993828/filgotinib-glpg0634-gs-6034-an-oral-selective-jak1-inhibitor-is-effective-as-monotherapy-in-patients-with-active-rheumatoid-arthritis-results-from-a-randomised-dose-finding-study-darwin-2
#3
A Kavanaugh, J Kremer, L Ponce, R Cseuz, O V Reshetko, M Stanislavchuk, M Greenwald, A Van der Aa, F Vanhoutte, C Tasset, P Harrison
OBJECTIVES: To evaluate the efficacy and safety of different doses of filgotinib, an oral Janus kinase 1 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA) and previous inadequate response to methotrexate (MTX). METHODS: In this 24-week phase IIb study, patients with moderately to severely active RA were randomised (1:1:1:1) to receive 50, 100 or 200 mg filgotinib once daily, or placebo, after a ≥4-week washout from MTX. The primary end point was the percentage of patients achieving an American College of Rheumatology (ACR)20 response at week 12...
December 19, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27964737/evidence-based-decision-support-for-pediatric-rheumatology-reduces-diagnostic-errors
#4
Michael M Segal, Balu Athreya, Mary Beth F Son, Irit Tirosh, Jonathan S Hausmann, Elizabeth Y N Ang, David Zurakowski, Lynn K Feldman, Robert P Sundel
BACKGROUND: The number of trained specialists world-wide is insufficient to serve all children with pediatric rheumatologic disorders, even in the countries with robust medical resources. We evaluated the potential of diagnostic decision support software (DDSS) to alleviate this shortage by assessing the ability of such software to improve the diagnostic accuracy of non-specialists. METHODS: Using vignettes of actual clinical cases, clinician testers generated a differential diagnosis before and after using diagnostic decision support software...
December 13, 2016: Pediatric Rheumatology Online Journal
https://www.readbyqxmd.com/read/27863807/head-to-head-comparison-of-certolizumab-pegol-versus-adalimumab-in-rheumatoid-arthritis-2-year-efficacy-and-safety-results-from-the-randomised-exxelerate-study
#5
Josef S Smolen, Gerd-Rüdiger Burmester, Bernard Combe, Jeffrey R Curtis, Stephen Hall, Boulos Haraoui, Ronald van Vollenhoven, Christopher Cioffi, Cécile Ecoffet, Leon Gervitz, Lucian Ionescu, Luke Peterson, Roy Fleischmann
BACKGROUND: To date, head-to-head trials comparing the efficacy and safety of biological disease-modifying antirheumatic drugs within the same class, including TNF inhibitors, in patients with active rheumatoid arthritis despite methotrexate therapy are lacking. We aimed to compare the efficacy and safety of two different TNF inhibitors and to assess the efficacy and safety of switching to the other TNF inhibitor without a washout period after insufficient primary response to the first TNF inhibitor at week 12...
December 3, 2016: Lancet
https://www.readbyqxmd.com/read/27860410/sarilumab-and-non-biologic-disease-modifying-antirheumatic-drugs-in-patients-with-active-ra-and-inadequate-response-or-intolerance-to-tnf-inhibitors
#6
Roy Fleischmann, Janet van Adelsberg, Yong Lin, Geraldo da Rocha Castelar-Pinheiro, Jan Brzezicki, Pawel Hrycaj, Neil M H Graham, Hubert van Hoogstraten, Deborah Bauer, Gerd R Burmester
OBJECTIVE: To evaluate efficacy and safety of sarilumab plus conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with active, moderate-to-severe rheumatoid arthritis (RA) with inadequate response or intolerance to anti-tumor necrosis factor (TNF) therapies. METHODS: Patients were randomly allocated to receive sarilumab 150 mg, sarilumab 200 mg, or placebo every 2 weeks (q2w) for 24 weeks with background csDMARD(s). Coprimary endpoints were proportion of patients achieving American College of Rheumatology 20% (ACR20) response at week 24 and change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at week 12...
November 17, 2016: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/27843372/wissler-fanconi-syndrome-and-related-diagnoses-a-case-report
#7
Mustafa Q Albustani, Robert F Howard
INTRODUCTION: Wissler-Fanconi syndrome is a rare rheumatic syndrome that was first described during the 1940s in Europe. Since then, many papers have been written that cover all aspects of this syndrome, most of which are in French and German language, with only a very few in English (none of them recent). We report here a case that fulfils the criteria for Wissler-Fanconi syndrome. Under the more general descriptive umbrella of Wissler-Fanconi syndrome, our patient also fulfils the Modified Jones criteria, and the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for rheumatoid arthritis, and was interpreted by other internists and another rheumatologist as fulfilling the Yamaguchi criteria for adult onset Still's disease...
2016: Open Access Rheumatol
https://www.readbyqxmd.com/read/27821272/targeting-cytokine-signaling-in-autoimmunity-back-to-the-future-and-beyond
#8
REVIEW
Kiyoshi Hirahara, Daniella Schwartz, Massimo Gadina, Yuka Kanno, John J O'Shea
Cytokines represent structurally diverse soluble factors with critical roles in normal immune function and the pathogenesis of autoimmunity. The emergence of many successful biological therapies targeting cytokines and cytokine receptors exemplifies the importance of cytokines in driving human autoimmune disease; unsurprisingly, there is no paucity of reviews on this subject. Nonetheless, many patients with autoimmune disease do not respond to biologicals, and cure remains an unmet goal. Thus, targeting the intracellular pathways employed by cytokines provides new therapeutic opportunities...
December 2016: Current Opinion in Immunology
https://www.readbyqxmd.com/read/27813423/emerging-drugs-and-therapeutics-for-systemic-sclerosis
#9
Jason J Lee, Janet E Pope
Treatment of systemic sclerosis (SSc) is challenging despite advances in medical therapeutics for other rheumatologic diseases. Significant disease modifying therapy is lacking for most patients with SSc, due to the heterogeneous multisystem nature of SSc and its complex pathophysiology. The emergence of organ based management strategies has provided guidance in patient care as well as research and drug development. Areas covered: Design and development of new compounds focused on the underlying fibrotic disease processes have been sparse...
December 2016: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/27803964/adrenal-crisis-while-on-high-dose-steroid-treatment-what-rheumatologist-should-consider
#10
REVIEW
Döndü Üsküdar Cansu, Güven Barış Cansu, Deniz Arik, Cengiz Korkmaz
Steroid treatment is commonly recommended for autoimmune disorders in rheumatology practice. While adrenal crisis may occur upon existence of an inducing factor in patients with known or unknown adrenal insufficiency as well as in those with a suppressed hypothalamic-pituitary-adrenal (HPA) axis due to chronic steroid use, addisonian crisis rarely develops in patients on supraphysiological doses of steroid and, when emerged, it might be very difficult to recognize. Here, we present a patient who developed adrenal crisis while receiving high-dose methylprednisolone treatment due to retroperitoneal fibrosis and we also discuss possible mechanisms with a brief literature review...
November 1, 2016: Rheumatology International
https://www.readbyqxmd.com/read/27797750/social-media-use-among-young-rheumatologists-and-basic-scientists-results-of-an-international-survey-by-the-emerging-eular-network-emeunet
#11
Elena Nikiphorou, Paul Studenic, Christian Gytz Ammitzbøll, Mary Canavan, Meghna Jani, Caroline Ospelt, Francis Berenbaum
OBJECTIVES: To explore perceptions, barriers and patterns of social media (SM) use among rheumatology fellows and basic scientists. METHODS: An online survey was disseminated via Twitter, Facebook and by email to members of the Emerging European League Against Rheumatism Network. Questions focused on general demographics, frequency and types of SM use, reasons and barriers to SM use. RESULTS: Of 233 respondents (47 countries), 72% were aged 30-39 years, 66% female...
October 24, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27796482/-therapeutic-administration-of-immunoglobulins
#12
T Witte
BACKGROUND: Intravenously administered immunoglobulins have multiple modes of action that are anti-inflammatory. They can therefore be beneficial in a number of autoimmune disorders. OBJECTIVE: The aim of this article is to analyze and summarize studies on the administration of intravenous immunoglobulins in rheumatological diseases. METHODS: A selective search and analysis of the literature was carried out related to the mode of action and efficacy of intravenous immunoglobulins in rheumatological diseases...
December 2016: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/27752360/cancer-immunotherapy-induced-rheumatic-diseases-emerge-as-new-clinical-entities
#13
Laura C Cappelli, Ami A Shah, Clifton O Bingham
Immune checkpoint inhibitors (ICIs) are newly approved treatments for advanced malignancies that are increasing survival. The mechanism of these drugs, non-specifically activating T cells, also leads to immune-mediated damage of tissue or immune-related adverse events (IRAE). IRAEs with rheumatic phenotypes are increasingly being recognised. Inflammatory arthritis, sicca syndrome, inflammatory myopathy, vasculitis and lupus nephritis have been described as a result of ICIs. Use of ICIs will be expanding in the coming years for several reasons...
2016: RMD Open
https://www.readbyqxmd.com/read/27748083/peficitinib-a-jak-inhibitor-in-the-treatment-of-moderate-to-severe-rheumatoid-arthritis-in-methotrexate-inadequate-responders
#14
A J Kivitz, S R Gutierrez-Ureña, J Poiley, M C Genovese, R Kristy, K Shay, X Wang, J P Garg, A Zubrzycka-Sienkiewicz
OBJECTIVE: To evaluate efficacy and safety of orally administered once-daily peficitinib in combination with methotrexate (MTX) in patients with moderate-to-severe rheumatoid arthritis (RA) who had an inadequate response to MTX. METHODS: In this multinational, phase IIb, randomized, double-blind, placebo-controlled, dose-ranging trial, patients with RA (N=378) were treated with peficitinib 25 mg, 50 mg, 100 mg, 150 mg + MTX, or matching placebo + MTX once daily for 12 weeks (NCT01554696)...
October 16, 2016: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/27733939/max-hirsch-1875-1941-his-forgotten-fate-and-his-contributions-to-the-founding-of-modern-rheumatology
#15
Wolfgang Keitel, Leif Olsson, Eric L Matteson
OBJECTIVE: To elucidate the connections between balneology and rheumatology in the founding period of the discipline of rheumatology, and describe the contributions of Max Hirsch, MD in the formation of professional rheumatology societies. MATERIAL AND METHODS: Historical documents from the medical history collection of Vogelsang-Gommern, Germany, and original personal documents of the Hirsch family and information from the medical and historical period literature were used in developing this report...
September 2016: European Journal of Rheumatology
https://www.readbyqxmd.com/read/27726163/efficacy-and-safety-of-ixekizumab-treatment-for-japanese-patients-with-moderate-to-severe-plaque-psoriasis-erythrodermic-psoriasis-and-generalized-pustular-psoriasis-results-from-a-52-week-open-label-phase-3-study-uncover-j
#16
Hidehisa Saeki, Hidemi Nakagawa, Ko Nakajo, Taeko Ishii, Yoji Morisaki, Takehiro Aoki, Gregory S Cameron, Olawale O Osuntokun
Psoriasis, a chronic, immune-mediated skin disease characterized by red, scaly plaques, affects approximately 0.3% of the population in Japan. The aim of this open-label study was to evaluate the long-term efficacy and safety of ixekizumab, a humanized, anti-interleukin-17A monoclonal antibody, in Japanese patients with plaque psoriasis (n = 78, including 11 psoriatic arthritis), erythrodermic psoriasis (n = 8) and generalized pustular psoriasis (n = 5). Ixekizumab was administrated s.c. at baseline (week 0, 160 mg), from weeks 2 to 12 (80 mg every 2 weeks), and from weeks 16 to 52 (80 mg every 4 weeks)...
October 11, 2016: Journal of Dermatology
https://www.readbyqxmd.com/read/27723271/baricitinib-methotrexate-or-combination-in-patients-with-rheumatoid-arthritis-and-no-or-limited-prior-disease-modifying-antirheumatic-drug-treatment
#17
Roy Fleischmann, Michael Schiff, Désirée van der Heijde, Cesar Ramos-Remus, Alberto Spindler, Marina Stanislav, Cristiano A F Zerbini, Sirel Gurbuz, Christina Dickson, Stephanie de Bono, Douglas Schlichting, Scott Beattie, Wen-Ling Kuo, Terence Rooney, William Macias, Tsutomu Takeuchi
Objective This Phase 3 study evaluated baricitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, as monotherapy or combined with methotrexate (MTX) compared to MTX in patients with active rheumatoid arthritis (RA) with no or minimal prior conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) and naive to biologic DMARDs. Methods Patients (N=588) were randomized 4:3:4 (MTX: baricitinib 4 mg once daily: baricitinib 4 mg + MTX) for 52 weeks. The primary endpoint assessment was noninferiority of baricitinib monotherapy to MTX based on American College of Rheumatology 20% (ACR20) response at Week 24...
October 9, 2016: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/27721659/rate-of-proven-rheumatic-diseases-in-a-large-collective-of-referrals-to-an-outpatient-rheumatology-clinic-under-routine-conditions
#18
Martin Feuchtenberger, Axel Philipp Nigg, Michael Rupert Kraus, Arne Schäfer
The prognostic significance of early diagnosis and therapeutic intervention in inflammatory rheumatic diseases has been well documented. However, a shortage of rheumatologists often impedes this approach in clinical practice. Therefore, it is of importance to identify those patients referred for diagnosis who would benefit most from a specialist's care. We applied a telephone-based triage for appointment allocation during routine care. This retrospective, monocentric analysis evaluated the efficacy of our triage to identify patients with rheumatic disease with special regard to initial appointment category (elective, early arthritis clinic (EAC), or emergency appointment)...
2016: Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders
https://www.readbyqxmd.com/read/27695278/vitamin-d-deficiency-in-egyptian-systemic-lupus-erythematosus-patients-how-prevalent-and-does-it-impact-disease-activity
#19
Nouran M Abaza, Reem M El-Mallah, Asmaa Shaaban, Sameh A Mobasher, Khaled F Al-Hassanein, Amr A Abdel Zaher, Rania H El-Kabarity
BACKGROUND: The emerging role of vitamin D in immunology and autoimmune disorders has been a worldwide interest in the last decade. Systemic lupus erythematosus (SLE) patients are particularly at a delicate position predisposing them to suffer from vitamin D deficiency due to the multiple risk factors accompanying the disease. Whether vitamin D deficiency is also involved as a risk factor for developing SLE and affecting its course is a considerable concern. OBJECTIVES: The objective of this study was to estimate the prevalence of vitamin D deficiency in SLE patients and its relation to disease...
2016: Integrative Medicine Insights
https://www.readbyqxmd.com/read/27684358/behcet-s-syndrome-in-nonendemic-regions
#20
Pietro Leccese, Yusuf Yazici, Ignazio Olivieri
PURPOSE OF REVIEW: Behcet's syndrome is more common in certain geographic regions, however, can be seen outside of these areas and need to be included in the differential diagnosis of many patients, as it has overlapping features with many rheumatologic conditions. RECENT FINDINGS: Especially in regions with immigrant populations, there seem to be similarities to originating countries in Behcet's prevalence, but the syndrome is not limited to those from certain backgrounds and can be seen in others also...
January 2017: Current Opinion in Rheumatology
keyword
keyword
97091
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"